Edition:
United States

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

13.75USD
3:59pm EST
Change (% chg)

$0.24 (+1.78%)
Prev Close
$13.51
Open
$13.50
Day's High
$13.82
Day's Low
$13.50
Volume
34,444
Avg. Vol
37,282
52-wk High
$19.50
52-wk Low
$12.20

Select another date:

Tue, Nov 21 2017

BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​

* Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​

BRIEF-Oxford Immunotec Global Q3 loss per share $0.70

* Oxford Immunotec reports third quarter 2017 financial results

Oxford Immunotec loses bid to block rival's blood test on patent grounds

By Nate Raymond A federal judge has declined to block Qiagen NV from bringing to market a blood test used to detect tuberculosis that competitor Oxford Immunotec Global PLC contends infringes patents on its own diagnostic kit.

BRIEF-Oxford Immunotec announces update in patent infringement litigation

* Oxford Immunotec announces update in patent infringement litigation

BRIEF-Oxford Immunotec updates on amendment to supply agreement with StemCell Technologies ​

* Oxford Immunotec Global PLC - ‍on Sept 1 unit entered into second amendment to supply agreement with StemCell Technologies Canada f/k/a StemCell Technologies ​

BRIEF-Oxford Immunotec appoints Stefan Linn as COO

* Oxford Immunotec appoints Stefan Linn as chief operating officer Source text for Eikon: Further company coverage:

BRIEF-Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares

* Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares

BRIEF-Oxford Immunotec Global announces agreement to sell 2.5 mln ordinary shares

* Oxford Immunotec Global Plc announces agreement to sell 2,500,000 ordinary shares

BRIEF-Oxford Immunotec Q2 loss per share $0.74

* Oxford immunotec reports second quarter 2017 financial results

BRIEF-Oxford Immunotec Global says unit entered into amendment to marketing authorization holder agreement with Riken Genesis

* Oxford Immunotec Global Plc - on july 24, unit of co entered into amendment to marketing authorization holder agreement with Riken Genesis Co., Ltd

Select another date: